Alcoholic Liver Disease/Nonalcoholic Fatty Liver Disease Index for Classification of Patients with Steatotic Liver Disease.

IF 4.7 Q1 ENDOCRINOLOGY & METABOLISM
Journal of Obesity & Metabolic Syndrome Pub Date : 2024-09-30 Epub Date: 2024-08-05 DOI:10.7570/jomes23063
Akash Roy, Arka De, Anand V Kulkarni, Surabhi Jajodia, Usha Goenka, Awanish Tewari, Nikhil Sonthalia, Mahesh K Goenka
{"title":"Alcoholic Liver Disease/Nonalcoholic Fatty Liver Disease Index for Classification of Patients with Steatotic Liver Disease.","authors":"Akash Roy, Arka De, Anand V Kulkarni, Surabhi Jajodia, Usha Goenka, Awanish Tewari, Nikhil Sonthalia, Mahesh K Goenka","doi":"10.7570/jomes23063","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Steatotic liver disease (SLD) encompasses metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-associated liver disease (AALD) at extremes as well as an overlap group termed MASLD with increased alcohol intake (MetALD). The Alcoholic Liver Disease/Nonalcoholic Fatty Liver Disease Index (ANI) was proposed to differentiate ALD from nonalcoholic fatty liver disease (NAFLD). We analysed the performance of the ANI in differentiating within the SLD spectrum.</p><p><strong>Methods: </strong>In a cross-sectional study at a tertiary care center, 202 adults (>18 years) who were prospectively diagnosed with SLD defined by magnetic resonance imaging-proton density fat fraction >6.4% were enrolled. Alcohol consumption (AC) was recorded according to thresholds for significant AC: 140-350 g/week (or 20-50 g/day) for females and 210-420 g/week (or 30-60 g/day) for males. The ANI was calculated, and area under the receiver operating characteristic curve (AUROC) was generated.</p><p><strong>Results: </strong>Of 202 patients (47 years [interquartile range, IQR, 38 to 55], 23.75% females, 77% obese, 42.1% with diabetes, 38.1% hypertensive, 28.7% statin use), 40.5% were ever-alcohol consumers; 120 (59%), 50 (24.7%), and 32 (15.8%) were MASLD (ANI, -3.7 [IQR, -7 to -1.6]; MetALD, - 1.45 [IQR, -2.4 to 0.28]; and AALD, 0.71 [IQR, -1.3 to 4.8], respectively; <i>P</i><0.05 for all). The AUROC of the ANI for MASLD and AALD was 0.79 (IQR, 0.72 to 0.84; cut-off <-3.5) and 0.80 (IQR, 0.74 to 0.86; cut-off >-1.49), respectively. The ANI outperformed aspartate transaminase/alanine transaminase (AST/ALT) ratio (AUROC=0.75 [IQR, 0.69 to 0.81]) and gamma glutamyl transpeptidase (GGT) (AUROC=0.74 [IQR, 0.67 to 0.80]). Addition of GGT did not improve model performance (AUC<sub>diff</sub>=0.004; <i>P</i>=0.33).</p><p><strong>Conclusion: </strong>AC is common in MASLD. The ANI distinguishes MASLD and AALD, with individual cut-offs within the intermediate zone indicating MetALD. ANI also outperforms AST/ALT ratio or GGT.</p>","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":" ","pages":"222-228"},"PeriodicalIF":4.7000,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11443332/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Obesity & Metabolic Syndrome","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7570/jomes23063","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/5 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Steatotic liver disease (SLD) encompasses metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-associated liver disease (AALD) at extremes as well as an overlap group termed MASLD with increased alcohol intake (MetALD). The Alcoholic Liver Disease/Nonalcoholic Fatty Liver Disease Index (ANI) was proposed to differentiate ALD from nonalcoholic fatty liver disease (NAFLD). We analysed the performance of the ANI in differentiating within the SLD spectrum.

Methods: In a cross-sectional study at a tertiary care center, 202 adults (>18 years) who were prospectively diagnosed with SLD defined by magnetic resonance imaging-proton density fat fraction >6.4% were enrolled. Alcohol consumption (AC) was recorded according to thresholds for significant AC: 140-350 g/week (or 20-50 g/day) for females and 210-420 g/week (or 30-60 g/day) for males. The ANI was calculated, and area under the receiver operating characteristic curve (AUROC) was generated.

Results: Of 202 patients (47 years [interquartile range, IQR, 38 to 55], 23.75% females, 77% obese, 42.1% with diabetes, 38.1% hypertensive, 28.7% statin use), 40.5% were ever-alcohol consumers; 120 (59%), 50 (24.7%), and 32 (15.8%) were MASLD (ANI, -3.7 [IQR, -7 to -1.6]; MetALD, - 1.45 [IQR, -2.4 to 0.28]; and AALD, 0.71 [IQR, -1.3 to 4.8], respectively; P<0.05 for all). The AUROC of the ANI for MASLD and AALD was 0.79 (IQR, 0.72 to 0.84; cut-off <-3.5) and 0.80 (IQR, 0.74 to 0.86; cut-off >-1.49), respectively. The ANI outperformed aspartate transaminase/alanine transaminase (AST/ALT) ratio (AUROC=0.75 [IQR, 0.69 to 0.81]) and gamma glutamyl transpeptidase (GGT) (AUROC=0.74 [IQR, 0.67 to 0.80]). Addition of GGT did not improve model performance (AUCdiff=0.004; P=0.33).

Conclusion: AC is common in MASLD. The ANI distinguishes MASLD and AALD, with individual cut-offs within the intermediate zone indicating MetALD. ANI also outperforms AST/ALT ratio or GGT.

用于脂肪肝患者分类的酒精性肝病/非酒精性脂肪肝指数。
背景:脂肪性肝病(SLD)包括代谢功能障碍相关脂肪性肝病(MASLD)和酒精相关肝病(AALD)两个极端,以及被称为酒精摄入增加相关脂肪性肝病(MASLD)(Met-ALD)的重叠组。酒精性肝病/非酒精性脂肪肝指数(ANI)是用来区分酒精性肝病和非酒精性脂肪肝的。我们分析了ANI在区分SLD谱系中的表现:在一家三级医疗中心进行的一项横断面研究中,我们招募了 202 名成人(大于 18 岁),他们通过磁共振成像-质子密度脂肪分数大于 6.4% 被前瞻性诊断为 SLD。酒精消耗量(AC)按照显著 AC 的阈值进行记录:女性为 140-350 克/周(或 20-50 克/天),男性为 210-420 克/周(或 30-60 克/天)。计算 ANI 并生成接收者操作特征曲线下面积 (AUROC):在 202 名患者(47 岁[四分位数间距,IQR,38 至 55],23.75% 女性,77% 肥胖,42.1% 糖尿病,38.1% 高血压,28.7% 使用他汀类药物)中,40.5% 曾经饮酒;120 人(59%)、50 人(24.7%)和 32 人(15.8%)为 MASLD(分别为 ANI,-3.7 [IQR,-7 至 -1.6] ;Met-ALD,-1.45 [IQR,-2.4 至 0.28] ;AALD,0.71 [IQR,-1.3 至 4.8];P-1.49)。ANI优于天冬氨酸转氨酶/丙氨酸转氨酶(AST/ALT)比值(AUROC=0.75 [0.69 至 0.81])和γ谷氨酰转肽酶(GGT)(AUROC=0.74 [0.67 至 0.80])。加入 GGT 并未改善模型性能(AUCdiff=0.004;P=0.33):结论:AC 在 MASLD 中很常见。ANI可区分MASLD和AALD,中间区域的个别临界值表示Met-ALD。ANI 也优于 AST/ALT 比值或 GGT。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Obesity & Metabolic Syndrome
Journal of Obesity & Metabolic Syndrome ENDOCRINOLOGY & METABOLISM-
CiteScore
8.30
自引率
9.60%
发文量
39
审稿时长
19 weeks
期刊介绍: The journal was launched in 1992 and diverse studies on obesity have been published under the title of Journal of Korean Society for the Study of Obesity until 2004. Since 2017, volume 26, the title is now the Journal of Obesity & Metabolic Syndrome (pISSN 2508-6235, eISSN 2508-7576). The journal is published quarterly on March 30th, June 30th, September 30th and December 30th. The official title of the journal is now "Journal of Obesity & Metabolic Syndrome" and the abbreviated title is "J Obes Metab Syndr". Index words from medical subject headings (MeSH) list of Index Medicus are included in each article to facilitate article search. Some or all of the articles of this journal are included in the index of PubMed, PubMed Central, Scopus, Embase, DOAJ, Ebsco, KCI, KoreaMed, KoMCI, Science Central, Crossref Metadata Search, Google Scholar, and Emerging Sources Citation Index (ESCI).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信